Longitudinal studies assessing the clinical outcomes and therapeutic responses associated with cytoinclusion-based PD-L1 expression profiling are also needed to elucidate its potential role in guiding personalized treatment strategies and improving patient outcomes in bladder cancer. This evidence concerns the gene CD274 and urinary bladder cancer.